Asymchem Laboratories (06821) saw its shares rise more than 10%, reaching a price of HK$115.5 at the time of writing, with a trading volume of HK$172 million. The surge follows the company's release of its first-quarter 2026 financial results on the evening of April 27. The report showed revenue of approximately RMB 1.802 billion, a year-on-year increase of 16.91%. However, net profit attributable to shareholders of the listed company was about RMB 304 million, a decrease of 6.82% compared to the same period last year. The company attributed the decline in net profit primarily to higher exchange losses due to the appreciation of the Renminbi, whereas it had recorded exchange gains in the prior-year period. On an adjusted basis, net profit attributable to shareholders was RMB 423 million, representing a significant increase of 27.91% year-on-year.

Breaking down the performance by business segment, revenue from the small-molecule CDMO business in the first quarter was RMB 1.2 billion, up a modest 0.43% year-on-year, but showing a 3.26% growth at constant exchange rates. In contrast, revenue from emerging businesses surged to RMB 598 million, a substantial increase of 74.07% year-on-year, driven mainly by strong growth in the chemical macromolecules and biomacromolecules segments. Huatai Securities commented that the company forecasts its full-year 2026 revenue will achieve a year-on-year growth of 19% to 22. Considering Asymchem's leading technological processes and the continued strong performance of its emerging businesses, the securities firm is optimistic about the company's prospects for rapid development throughout 2026.